22.17USDMkt Cap: 2.83B USDP/E: —Last update: 2026-05-21
Alumis Inc., a clinical stage biopharmaceutical company, focuses on the development and commercialization of medicines for autoimmune disorders. The company offers envudeucitinib, a tyrosine kinase 2 (TYK2) inhibitor for…
Industry Peers
Biotechnologyloading…
Indicators:|
Key Statistics
Company
Market Cap2.83B USD
Enterprise Value2.34B USD
Revenue (TTM)8.40M USD
Gross Profit8.40M USD
Net Income (TTM)-243.32M USD
Revenue/Share0.0820 USD
Last Price22.17 USD
Fiscal Year EndDec 2025
MR QuarterMar 2026
Employees225
CountryUS
SectorHealthcare
IndustryBiotechnology
ISIN—
Valuation
P/E (Trailing)—
P/E (Forward)-7.51
PEG—
EV/EBITDA-5.37
EV/Revenue278.41
P/S336.41
P/B4.97
EPS (TTM)-1.78
EPS (Forward)-2.95
52W Range
21.4873% of range22.43
52W High22.43 USD
52W Low21.48 USD
Profitability
Gross Margin100.00%
Oper. Margin-5652.44%
EBITDA Margin0.00%
Profit Margin-1011.75%
ROE-80.76%
ROA-59.07%
Growth
Revenue Growth-90.00%
Earnings Growth—
Cash Flow & Leverage
Operating CF-369.52M USD
CapEx (TTM)653.00K USD
FCF Margin-2460.78%
FCF Yield-7.31%
Net Debt-487.28M USD
Net Debt/EBITDA1.12
Balance Sheet
Debt/Equity0.12
Current Ratio7.51
Quick Ratio7.41
Book Value/Sh4.457 USD
Cash/Share4.102 USD
Dividends
Fwd Div Rate—
Trail. Div Rate0.0000 USD
Div. Yield—
5Y Avg Yield—
Payout Ratio0.00%
Ex-Div Date—
Pay Date—
Analyst Consensus
Rating1.3 (Strong Buy)
Target (Mean)40.10 USD
Target Range25.00 USD – 55.00 USD
# Analysts10
Ownership
Shares Out.123.43M
Float101.01M
Insiders0.62%
Institutions99.68%
Short Interest
Short Ratio7.4d
Short % Float16.20%
Short % Out.8.87%
Shares Short11.29M
Short (prev mo.)11.23M
Technical
SMA 5024.00 (-7.6%)
SMA 20015.01 (+47.7%)
Beta—
S&P 52W Chg28.31%
Avg Vol (30d)823.57K
Avg Vol (10d)908.75K
Technical Indicators
RSI (14)—
MACD—
MACD Signal—
MACD Hist.—
BB Upper—
BB Middle—
BB Lower—
BB Width—
ATR (14)—
Vol Ratio (20d)—